The largest and longest study of the obesity drug Wegovy has shown people maintain significant weight loss for at least four years, with fewer serious adverse events than those given placebo ...
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount of weight they lose while on the drug, researchers have found.
The weight loss jab helped obese people lose a fifth of their weight within 72 weeks, and the weekly injection is being ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Patients taking Novo Nordisk’s anti-obesity jab sustained weight loss for up to four years and had a ...
A large, long-term trial of the weight-loss medication Wegovy (semaglutide) found that people tended to lose weight over the first 65 weeks on the drug—about one year and three months—but then ...
Adults who were overweight or had obesity and took Wegovy (semaglutide) lost an average of 10 percent of their body weight — and kept it off — after four years on the drug. Semaglutide may ...
The revolutionary jabs were a hot topic as more than 40,000 cancer experts gathered in Chicago for the world's largest cancer ...
Mounjaro given green light for use on the health service for people with a BMI of at least 35 following soaring demand for ...
VENICE, Italy — Four-year data from the SELECT cardiovascular outcomes trial show that the anti-obesity drug semaglutide (Wegovy) leads to clinically significant and durable weight loss, as well ...
Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support a global market worth an eye-watering $60 billion within the next decade, according to a ...